Prescription Anti-Epilepsy Drug Zonisamide Recalled for Manufacturing Deviations
Glenmark Pharmaceuticals is recalling Zonisamide Capsules (100 mg) due to current good manufacturing practice (cGMP) deviations. Two lots were distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a voluntary, firm-initiated Class II recall for manufacturing compliance deviations with no reported illnesses or injuries. The hazard is a manufacturing process issue rather than a contamination or defect with evidence of harm, consistent with precautionary recalls classified as Moderate.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Zonisamide Capsules, USP, 100 mg, due to deviations from current good manufacturing practices (cGMP). The affected product is packaged in two sizes: 100-count bottles (NDC 68462-130-01) and 500-count bottles (NDC 68462-130-05).
Two lots are subject to recall: Lot 29200053 with approximately 7,044 bottles of the 100-count size (expiring 4/30/2023), and Lot 29200054 with approximately 1,014 bottles of the 500-count size (expiring 4/30/2023). Both lots were distributed throughout the United States.
Zonisamide is a prescription anti-epilepsy medication. Patients currently taking this medication who have bottles from the affected lots should contact their healthcare provider or pharmacist. Do not stop taking Zonisamide without medical guidance, as abrupt discontinuation could result in breakthrough seizures or loss of seizure control.
The recalled product
- Product
- ZONISAMIDE (ZONISAMIDE)
- Brand
- ZONISAMIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Anti-Epilepsy
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- a) Lot #: 29200053
- Exp 4/30/2023
- b) Lot #: 29200054
UPCs (3)
- 0368462130018
- 0368462129012
- 0368462128015
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 3 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same brand · ZONISAMIDE
- ModerateZonisamide Anti-Seizure Capsules Recalled Nationwide for Manufacturing Quality Control Issues
FDA (Drugs) · 2022-05-04
- ModerateDrug Recall: Zonisamide Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2022-05-04
- ModerateZonisamide Capsules Recalled by Glenmark Due to CGMP Deviations
FDA (Drugs) · 2021-09-29
- ModerateZonisamide Capsules Recalled for Manufacturing Deviations
FDA (Drugs) · 2021-09-29
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19